Anti-IgE Therapy in Allergic Rhinitis Management

Allergic rhinitis is driven by an IgE-mediated type 2 inflammatory cascade in which exposure to inhaled allergens triggers cross-linking of allergen-specific IgE on the high-affinity FcεRI receptor of mast cells and basophils. This interaction induces cellular degranulation and the release of histamine, leukotrienes and cytokines, leading to nasal congestion, rhinorrhoea, sneezing and pruritus. Anti-IgE therapy, exemplified by the monoclonal antibody omalizumab, binds circulating IgE, thereby reducing its availability to FcεRI and downmodulating receptor expression on effector cells. Clinical application of anti-IgE in allergic rhinitis has demonstrated significant reductions in symptom scores, decreased reliance on oral antihistamines and intranasal corticosteroids, and improvements in quality of life. Pre-seasonal dosing regimens have shown particular promise for seasonal allergic variants, offering prophylactic benefit by attenuating the immunological priming that occurs before pollen exposure. Beyond symptomatic relief, anti-IgE therapy may also alter the underlying allergic sensitisation profile and reduce the risk of progression to comorbid asthma. Overall, anti-IgE treatment represents a targeted, disease-modifying strategy that complements existing pharmacotherapy and allergen-specific immunotherapy in the global management of allergic rhinitis.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Anti-IgE Therapy in Allergic Rhinitis Management publication trend

The graph below shows the total number of articles in anti-ige therapy in allergic rhinitis management across all publications each year (not limited to Nature Index journals).

Technical terms

Immunoglobulin E (IgE): The class of antibody that binds to allergens and triggers release of inflammatory mediators from mast cells and basophils.

Omalizumab: A humanised monoclonal antibody that selectively binds free IgE, preventing its attachment to FcεRI receptors on immune effector cells.

FcεRI: The high-affinity receptor for IgE expressed on the surface of mast cells, basophils and dendritic cells, central to allergen-induced activation.

Combined Symptom and Medication Score (CSMS): An integrated outcome measure combining patient-reported symptom severity with rescue medication usage to quantify treatment benefit.

Subcutaneous immunotherapy (SCIT): A long-term treatment involving regular injections of allergen extracts to induce immunological tolerance and reduce allergic reactivity.

References

1. Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever. Frontiers in Immunology (2024).
2. Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis. Clinical and Translational Allergy (2022).
3. Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study. Frontiers in Immunology (2022).